Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?

Background: Upfront cytoreductive nephrectomy (CN) is no longer the standard of care for patients with metastastic renal cell carcinoma (mRCC) with intermediate or poor prognosis according to the International mRCC Database Consortium categories. Objective: To investigate indications for CN followin...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Elisabeth E. Fransen van de Putte, Luna van den Brink, Mohamed A. Mansour, Johannes C. van der Mijn, Sofie Wilgenhof, Johannes V. van Thienen, John B.A.G. Haanen, Ekaterini Boleti, Thomas Powles, Patricia J. Zondervan, Niels M. Graafland, Axel Bex
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2023-09-01
סדרה:	European Urology Open Science
נושאים:	Cytoreductive Ipilimumab Nephrectomy Nivolumab Indications
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2666168323003798
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!